Sodium zirconium cyclosilicate, also known as ZS-9, is indicated for the treatment of hyperkalemia in adult patients. ZS-9 is a non-absorbed, non-polymer, inorganic powder that has the ability to exchange potassium for sodium cations contained in its uniform microporous crystalline structure. It captures potassium throughout the entire GI tract and reduces the concentration of free potassium in the GI lumen, leading to an increase in fecal excretion, eventually leading to lowered serum potassium and resolution of hyperkalemia. Its high affinity for potassium ions is not influenced by the presence of other cations such as calcium and magnesium.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Sodium Zirconium Cyclosilicate, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.